MedTrace Logo

Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

NCT06461351 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-08-07

No results posted yet for this study

Summary

This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.

Conditions

  • B-cell Tumors

Interventions

OTHER

Inaticabtagene autoleucel Injection

Inaticabtagene autoleucel Injection

Sponsors & Collaborators

  • Juventas Cell Therapy Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianxiang Wang, Dr. · Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2039-05-30
Completion
2040-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06461351 on ClinicalTrials.gov